BR0012046A - Composto heterocìclico, composição farmacêutica, inibidor de ativação de ap-1 ou um inibidor da ativação de nf-kappab, inibidor da produção de citocina inflamatória, e, inibidor da produção de metaloprotease de matriz ou inibidor da expressão do fator de adesão de célula inflamatória - Google Patents
Composto heterocìclico, composição farmacêutica, inibidor de ativação de ap-1 ou um inibidor da ativação de nf-kappab, inibidor da produção de citocina inflamatória, e, inibidor da produção de metaloprotease de matriz ou inibidor da expressão do fator de adesão de célula inflamatóriaInfo
- Publication number
- BR0012046A BR0012046A BR0012046-4A BR0012046A BR0012046A BR 0012046 A BR0012046 A BR 0012046A BR 0012046 A BR0012046 A BR 0012046A BR 0012046 A BR0012046 A BR 0012046A
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitor
- activation
- production
- inflammatory
- heterocyclic compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"COMPOSTO HETEROCìCLICO, COMPOSIçãO FARMACêUTICA, INIBIDOR DE ATIVAçãO DE AP-1 OU UM INIBIDOR DA ATIVAçãO DE NF-KAPPAB, INIBIDOR DA PRODUçãO DE CITOCINA INFLAMATóRIA, E, INIBIDOR DA PRODUçãO DA METALOPROTEASE DE MATRIZ OU INIBIDOR DA EXPRESSãO DO FATOR DE ADESãO DE CéLULA INFLAMATóRIA". A presente invenção fornece um inibidor da ativação de AP-1, um inibidor da ativação de NF-kappaB, um inibidor da produção de citocina inflamatória, um inibidor da produção da metaloprotease de matriz ou um inibidor da expressão do fator de adesão de célula inflamatória, que contém um composto heterocíclico ou um sal deste farmaceuticamente aceitável as um ingrediente ativo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP18795999 | 1999-07-01 | ||
JP2000071706 | 2000-03-15 | ||
PCT/JP2000/004298 WO2001002359A1 (fr) | 1999-07-01 | 2000-06-29 | Composes heterocycliques et leurs applications en medecine |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0012046A true BR0012046A (pt) | 2002-05-14 |
Family
ID=26504663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0012046-4A BR0012046A (pt) | 1999-07-01 | 2000-06-29 | Composto heterocìclico, composição farmacêutica, inibidor de ativação de ap-1 ou um inibidor da ativação de nf-kappab, inibidor da produção de citocina inflamatória, e, inibidor da produção de metaloprotease de matriz ou inibidor da expressão do fator de adesão de célula inflamatória |
Country Status (11)
Country | Link |
---|---|
US (1) | US6794378B2 (pt) |
EP (1) | EP1193255A4 (pt) |
JP (1) | JP4609691B2 (pt) |
KR (1) | KR20020064147A (pt) |
CN (1) | CN1372548A (pt) |
AU (1) | AU5570600A (pt) |
BR (1) | BR0012046A (pt) |
CA (1) | CA2377771A1 (pt) |
MX (1) | MXPA02000253A (pt) |
TW (1) | TW519538B (pt) |
WO (1) | WO2001002359A1 (pt) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100398413B1 (ko) * | 1998-12-23 | 2003-12-18 | 주식회사 포스코 | 전로슬래그의백탁수생성방지방법 |
AU2002210989A1 (en) * | 2000-11-01 | 2002-05-15 | Ajinomoto Co., Inc. | Cyclopropanecarboxylic acid amide compounds and medicinal use thereof |
JP2004269356A (ja) * | 2000-12-27 | 2004-09-30 | Ajinomoto Co Inc | 創傷部癒着防止剤 |
US20050282814A1 (en) * | 2002-10-03 | 2005-12-22 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
JPWO2005018607A1 (ja) * | 2003-08-20 | 2007-11-01 | 味の素株式会社 | 溶解性を改善した医薬品製剤 |
WO2005092836A1 (en) * | 2004-03-15 | 2005-10-06 | Eli Lilly And Company | Opioid receptor antagonists |
NZ588139A (en) * | 2004-04-08 | 2012-02-24 | Targegen Inc | 7-Aryl-3-arylamino-benzo[1,2,4]triazine derivatives |
WO2006115509A2 (en) | 2004-06-24 | 2006-11-02 | Novartis Vaccines And Diagnostics Inc. | Small molecule immunopotentiators and assays for their detection |
EP1773797A2 (en) | 2004-08-06 | 2007-04-18 | Otsuka Pharmaceutical Co., Ltd. | Aromatic compounds |
MX2007002208A (es) | 2004-08-25 | 2007-05-08 | Targegen Inc | Compuestos hetrociclicos y metodos de uso. |
US20100196509A1 (en) | 2005-02-28 | 2010-08-05 | Jonathan Braun | Methods for Diagnosis and Treatment of Endometrial Cancer |
CA2600531A1 (en) * | 2005-03-16 | 2006-09-28 | Targegen, Inc. | Pyrimidine compounds and methods of use |
US8318906B2 (en) | 2005-04-15 | 2012-11-27 | The Regents Of The University Of California | EMP2 antibodies and their therapeutic uses |
US8648052B2 (en) * | 2005-04-15 | 2014-02-11 | The Regents Of The University Of California | Prevention of chlamydia infection using SIRNA |
WO2006113526A2 (en) | 2005-04-15 | 2006-10-26 | The Regents Of The University Of California | Prevention of chlamydia infection using a protective antibody |
AU2006254825A1 (en) * | 2005-06-08 | 2006-12-14 | Targegen, Inc. | Methods and compositions for the treatment of ocular disorders |
US7754717B2 (en) * | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
US8133900B2 (en) * | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
PT1951684T (pt) | 2005-11-01 | 2016-10-13 | Targegen Inc | Inibidores de cinases de tipo biaril-meta-pirimidina |
US20070161645A1 (en) * | 2005-11-02 | 2007-07-12 | Targegen, Inc. | Thiazole inhibitors targeting resistant kinase mutations |
MY146514A (en) | 2005-12-05 | 2012-08-15 | Otsuka Pharma Co Ltd | Diarylether derivatives as antitumor agents |
UA95978C2 (ru) | 2006-10-02 | 2011-09-26 | Оцука Фармас'Ютікел Ко., Лтд. | Ингибитор активации stat3/5 |
CL2008001626A1 (es) | 2007-06-05 | 2009-06-05 | Takeda Pharmaceuticals Co | Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer. |
DE102008031518A1 (de) * | 2007-07-30 | 2009-02-05 | Merck Patent Gmbh | Flüssigkristallanzeige |
WO2009025358A1 (ja) | 2007-08-23 | 2009-02-26 | Takeda Pharmaceutical Company Limited | 複素環化合物およびその用途 |
US9464135B2 (en) | 2007-10-08 | 2016-10-11 | The Regents Of The University Of California | Epithelial membrane protein-2 (EMP2) and proliferative vitroretinopathy (PVR) |
EP2399921B1 (en) | 2008-12-01 | 2015-08-12 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
CN102459185B (zh) | 2009-04-20 | 2015-06-03 | 田边三菱制药株式会社 | 新型甲状腺激素β受体激动剂 |
JP5847533B2 (ja) * | 2010-10-19 | 2016-01-27 | 田辺三菱製薬株式会社 | 新規甲状腺ホルモンβ受容体作動薬 |
WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
CN102993091A (zh) * | 2012-11-28 | 2013-03-27 | 张家港市大伟助剂有限公司 | 5-氨基-2-(4-氨基苯氧基)-吡啶的制备方法 |
CN104788410B (zh) * | 2014-01-22 | 2017-11-17 | 中国科学院上海药物研究所 | 一类苯环‑芳香环串联化合物、其制备方法和医药用途 |
WO2018081167A1 (en) | 2016-10-24 | 2018-05-03 | Yumanity Therapeutics | Compounds and uses thereof |
KR102162502B1 (ko) | 2017-05-22 | 2020-10-06 | 주식회사 엘지화학 | 액정 배향제용 중합체, 이를 포함하는 액정 배향제, 그리고 이를 이용한 액정배향막 및 액정표시소자 |
KR102020030B1 (ko) | 2017-08-24 | 2019-09-10 | 주식회사 엘지화학 | 액정 배향제용 중합체, 이를 포함하는 액정 배향제 조성물, 그리고 이를 이용한 액정배향막 및 액정표시소자 |
CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
EA202092225A1 (ru) * | 2018-03-23 | 2021-02-09 | Юманити Терапьютикс, Инк. | Соединения и их применение |
KR102235476B1 (ko) | 2018-03-30 | 2021-04-01 | 주식회사 엘지화학 | 액정 배향제 조성물, 이를 이용한 액정 배향막의 제조 방법, 및 이를 이용한 액정 배향막 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0102476B1 (en) * | 1982-08-06 | 1986-11-05 | American Cyanamid Company | Method of modulating the immune response system in mammals |
IT1262921B (it) * | 1992-01-10 | 1996-07-22 | Federico Arcamone | Agenti antitumorali analoghi di oligopeptidi pirrol-amidinici retroversi processi di preparazione e prodotti farmaceutici che li contengono |
JP2000500464A (ja) * | 1995-11-13 | 2000-01-18 | スミスクライン・ビーチャム・コーポレイション | 血液調節化合物 |
WO1997024343A1 (en) * | 1995-12-29 | 1997-07-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Phenyl thiazole derivatives with anti herpes virus properties |
IL134723A0 (en) * | 1997-09-23 | 2001-04-30 | Zeneca Ltd | Amide derivatives for the treatment of diseases mediated by cytokines |
NZ508413A (en) * | 1998-05-22 | 2003-08-29 | Avanir Pharmaceuticals | Benzimidazole analogs as down-regulators of IgE |
RU2001106631A (ru) * | 1998-09-11 | 2004-03-20 | Адзиномото Ко., Инк. (Jp) | Производные бензола и их фармацевтическое применение |
AU6866700A (en) | 1999-09-01 | 2001-03-26 | Ajinomoto Co., Inc. | Biscyclopropanecarboxylic acid amide compounds and medicinal use thereof |
ATE277933T1 (de) * | 2000-06-06 | 2004-10-15 | Pfizer Prod Inc | Thiophenverbindungen zur verwendung als antikrebsmittel |
-
2000
- 2000-06-29 BR BR0012046-4A patent/BR0012046A/pt not_active IP Right Cessation
- 2000-06-29 MX MXPA02000253A patent/MXPA02000253A/es unknown
- 2000-06-29 JP JP2001507799A patent/JP4609691B2/ja not_active Expired - Fee Related
- 2000-06-29 AU AU55706/00A patent/AU5570600A/en not_active Abandoned
- 2000-06-29 KR KR1020017016913A patent/KR20020064147A/ko not_active Application Discontinuation
- 2000-06-29 EP EP00940879A patent/EP1193255A4/en not_active Withdrawn
- 2000-06-29 WO PCT/JP2000/004298 patent/WO2001002359A1/ja not_active Application Discontinuation
- 2000-06-29 CN CN00812370A patent/CN1372548A/zh active Pending
- 2000-06-29 CA CA002377771A patent/CA2377771A1/en not_active Abandoned
- 2000-06-30 TW TW089113050A patent/TW519538B/zh active
-
2001
- 2001-12-31 US US10/029,871 patent/US6794378B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1193255A4 (en) | 2002-08-07 |
MXPA02000253A (es) | 2002-06-21 |
US6794378B2 (en) | 2004-09-21 |
US20020133005A1 (en) | 2002-09-19 |
WO2001002359A1 (fr) | 2001-01-11 |
JP4609691B2 (ja) | 2011-01-12 |
EP1193255A1 (en) | 2002-04-03 |
TW519538B (en) | 2003-02-01 |
CN1372548A (zh) | 2002-10-02 |
AU5570600A (en) | 2001-01-22 |
KR20020064147A (ko) | 2002-08-07 |
CA2377771A1 (en) | 2001-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0012046A (pt) | Composto heterocìclico, composição farmacêutica, inibidor de ativação de ap-1 ou um inibidor da ativação de nf-kappab, inibidor da produção de citocina inflamatória, e, inibidor da produção de metaloprotease de matriz ou inibidor da expressão do fator de adesão de célula inflamatória | |
BRPI0507652A (pt) | composições farmacêuticas compreendendo um derivado de benzoidiazepina e um inibidor da proeìna de fusão de rsv | |
DE60019693D1 (de) | Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten | |
GEP20012388B (en) | Metalloproteinase Inhibitors, Pharmaceutical Compositions on Their Base, Use and Methods for Obtaining and Intermediates | |
NO20043913L (no) | Blandinger med modifisert frigjoring av i det minste en form av tramadol | |
BR0014320A (pt) | Composições de substâncias terapêuticas solúveis em tocol | |
TR200201505T2 (tr) | Terapötik maddeler olarak pirazolopirimidinler | |
NO20031024L (no) | Bicykliske pyrrolyl amider som glukogen fosforylase inhibitorer | |
BR0116452A (pt) | Composto, composição farmacêutica, uso de um composto | |
BG106030A (en) | Pharmaceutical composition | |
BR9913562A (pt) | Derivados de benzeno, inibidor de ativação de ap-1 e nf-capa b, inibidor de produção de citoquina inflamatória, inibidor de produção de metaloprotease matricial ou inibidor de aparecimento de fator de adesão de célula inflamatório, e, agente antiinflamatório, anti-reumático, imunossupressor, inibidor de metástase cancerosa, remédio para arterioesclerose e agente antiviral | |
CY1110906T1 (el) | Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης | |
NO962841D0 (no) | Anvendelse av 2-hydroksy-5-fenylazobenzosyrederivater som colon cancer kjemopreventativer og kjemoterapeutiske midler | |
SE0101932D0 (sv) | Pharmaceutical combinations | |
SE9603667D0 (sv) | Pharmaceutical compositions | |
BR0313385A (pt) | Derivados de pirimidina-2,4-diona como inibidores de metaloproteinase da matriz | |
BR0314797A (pt) | Derivados da pirimidineamida e o uso dos mesmos | |
BR0111678A (pt) | Composições medicinais contendo derivados de propenona | |
NO20010863L (no) | Nye orale formuleringer for 5-HT4-agonister eller - antagonister | |
BR0306928A (pt) | Composições farmacêuticas estáveis compreendendo inibidores de enzimas conversoras de angiotensina (ace) | |
EP1284272A4 (en) | Estra-1,3,5 (10) -triene | |
WO2002024697A1 (fr) | Composes spiro et inhibiteurs de molecules d'adhesion contenant ces composes comme ingredient actif | |
DE69931378D1 (de) | Chinazolin derivate und therapeutische verwendungen davon | |
NO983444D0 (no) | Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer | |
BR9807330A (pt) | Agentes inibidores do progresso de pterìgio e recorrência pós-operatória do mesmo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 4A, 5A, 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1927 DE 11/12/2007. |